Skip to main content
AVCRF
OTC Life Sciences

Avricore Health Reports Steep Revenue Decline and Going Concern Warning Amid Major Customer Loss

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.035
Mkt Cap
$3.57M
52W Low
$0.013
52W High
$0.254
Market data snapshot near publication time

summarizeSummary

The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.


check_boxKey Events

  • Going Concern Warning Issued

    Management disclosed a material uncertainty regarding the company's ability to continue as a going concern, citing historical operating losses and negative cash flows.

  • Significant Revenue Decline

    Revenue for the nine months ended September 30, 2025, plummeted 85% year-over-year to $500,433, primarily due to the expiration of a major customer agreement.

  • Shift to Comprehensive Loss

    The company reported a comprehensive loss of $916,042 for the nine-month period, a significant reversal from income in the prior year.

  • Cash Flow Deterioration

    Net cash used in operating activities resulted in a $600,111 decrease in cash and cash equivalents for the nine-month period.


auto_awesomeAnalysis

The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.

この提出時点で、AVCRFは$0.04で取引されており、市場はOTC、セクターはLife Sciences、時価総額は約$357万でした。 52週の取引レンジは$0.01から$0.25でした。 この提出書類はネガティブの市場センチメント、重要度スコア9/10と評価されました。

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed AVCRF - Latest Insights

AVCRF
Feb 17, 2026, 6:15 AM EST
Filing Type: 6-K
Importance Score:
8
AVCRF
Jan 12, 2026, 3:09 PM EST
Filing Type: 6-K
Importance Score:
9